Open an account

Stablecoin Development

NBY · NYSE

$0.83−$0.0084 (−1.00%)TodayMarket closed ·
Prev close $0.8384

NBY analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated May 1, 2025

Bull case

NovaBay Pharmaceuticals Inc. has received a significant infusion of capital with an increased acquisition offer of $11.5 million, reflecting external validation of its business prospects. The company's revenue reached $2.4 million, which demonstrates a stable financial performance amid market expectations, although it fell slightly short of both internal estimates and consensus projections. Furthermore, despite acknowledging inherent valuation risks, there is confidence that the balance of risks and opportunities positions NovaBay favorably for future growth in the eye-care and related product sectors.

Bear case

NovaBay Pharmaceuticals Inc. reported a net loss of $2.2 million, translating to an earnings per share (EPS) of $(0.60), which significantly exceeded both internal estimates of $(0.28) and consensus expectations of $(0.30). The company faces multiple risks that could adversely impact its financial outlook, including potential failures in demonstrating safety and efficacy for its product candidates, difficulty in gaining regulatory approval, and challenges related to consumer acceptance and competition. Additionally, the lack of adjusted historical financials complicates the comparability of current results with those from previous periods, further contributing to uncertainty regarding the company’s performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.